Oncoquest is under clinical development by XEME BioPharma and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Oncoquest’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Oncoquest overview

Oncoquest vaccine is under development for the treatment of non-Hodgkin’s follicular lymphoma, solid tumors like platinum-resistant and relapsed ovarian cancer, chronic lymphocytic leukemia and early stage prostate cancer. The vaccine candidate is administered through subcutaneous route. It consists of patient-specific membrane proteins directly extracted from autologous tumor cells and incorporated into liposomes along with interleukin 2 (IL-2). The vaccine candidate is developed based on AGGREGON technology.

It was also under development for the treatment of solid tumors like lung cancer and colorectal cancer and hematological malignancies including multiple myeloma and acute myeloid leukemia. 

For a complete picture of Oncoquest’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.